Trial Profile
A Randomized, International, Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Adenocarcinoma; Thyroid cancer
- Focus Adverse reactions; Registrational
- Acronyms 88
- Sponsors AstraZeneca; AstraZeneca AB; Sanofi Genzyme
- 22 Sep 2023 Planned End Date changed from 29 Dec 2023 to 28 Jun 2024.
- 03 Oct 2022 Planned End Date changed from 31 Dec 2022 to 29 Dec 2023.
- 20 Oct 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.